09:05 EDT Siga Technologies falls 37% to $7.58 after mpox study failure
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIGA:
- Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released
- WHO to consider emergency as Mpox resurfaces in Africa, News Central reports
- Siga Technologies reports Q2 EPS 3c VS. (4c) last year
- SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
- SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX®